Compare Novartis AG (NVS) vs Energy Fuels Inc Ordinary Shares (Canada) (UUUU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Energy Fuels Inc Ordinary Shares (Canada) — how do they compare? Novartis AG trades at $148.84 (market cap $279.90B), while Energy Fuels Inc Ordinary Shares (Canada) trades at $8.31 (market cap $2.21B). The key difference: Novartis AG is far larger — about 126.7× Energy Fuels Inc Ordinary Shares (Canada)'s market cap, and Novartis AG pays a 3.23% dividend while Energy Fuels Inc Ordinary Shares (Canada) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Energy Fuels Inc Ordinary Shares (Canada) for 0 Days on average.
| NVS | UUUU | |
|---|---|---|
Market Cap | $279.90B | $2.21B |
Volume | 1,647,300 | 15,605,017 |
Sector | Health | Energy |
52-Week High | $168.62 | $27.72 |
52-Week Low | $121.80 | $8.34 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $321.22B | $1.95B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Energy Fuels Inc Ordinary Shares (Canada)
Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →
